Galapagos NV – Product Pipeline Review – 2012
SUMMARY
Global Market Direct’s pharmaceuticals report, “Galapagos NV Product Pipeline Review - 2012” provides data on the Galapagos NV’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Galapagos NV’s corporate website, SEC filings, investor presentations and featured press releases, both from Galapagos NV and industry-specific third party sources, put together by Global Markets Direct’s team.
SCOPE
SUMMARY
Global Market Direct’s pharmaceuticals report, “Galapagos NV Product Pipeline Review - 2012” provides data on the Galapagos NV’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Galapagos NV’s corporate website, SEC filings, investor presentations and featured press releases, both from Galapagos NV and industry-specific third party sources, put together by Global Markets Direct’s team.
SCOPE
- Galapagos NV - Brief Galapagos NV overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Galapagos NV human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Galapagos NV with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Galapagos NV’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
- Evaluate Galapagos NV’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Galapagos NV in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Galapagos NV’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Galapagos NV.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Galapagos NV and identify potential opportunities in those areas.
Galapagos NV Snapshot
Galapagos NV Overview
Key Information
Key Facts
Galapagos NV – Research and Development Overview
Key Therapeutic Areas
Galapagos NV – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Galapagos NV – Pipeline Products Glance
Galapagos NV Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Galapagos NV – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Galapagos NV – Drug Profiles
ADC-3322
Product Description
Mechanism of Action
R&D Progress
Antibody Program For Bone Disorders
Product Description
Mechanism of Action
R&D Progress
Cancer Program
Product Description
Mechanism of Action
R&D Progress
Drug For Alzheimer’s Disease
Product Description
Mechanism of Action
R&D Progress
Drug For COPD
Product Description
Mechanism of Action
R&D Progress
Drug For Cystic Fibrosis
Product Description
Mechanism of Action
R&D Progress
Drug For Diabetes And Obesity
Product Description
Mechanism of Action
R&D Progress
G-100192
Product Description
Mechanism of Action
R&D Progress
GLPG-0187
Product Description
Mechanism of Action
R&D Progress
GLPG-0492
Product Description
Mechanism of Action
R&D Progress
GLPG-0634
Product Description
Mechanism of Action
R&D Progress
GLPG-0974
Product Description
Mechanism of Action
R&D Progress
Osteoarthritis program
Product Description
Mechanism of Action
R&D Progress
Osteoporosis Program
Product Description
Mechanism of Action
R&D Progress
Galapagos NV – Pipeline Products by Route of Administration
Galapagos NV – Pipeline Products By Mechanism of Action
Galapagos NV – Recent Pipeline Updates
Galapagos NV - Dormant Projects
Galapagos NV - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
GLPG-0259
GLPG-0492
Galapagos NV – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Galapagos NV, Recent Developments
Galapagos NV- Press Release
Jun 05, 2012: Galapagos To Present GLPG0634 Phase II Proof Of Concept Results At EULAR Annual European Congress
May 14, 2012: Galapagos Initiates Phase IIa Study With GLPG0634
Feb 29, 2012: Abbott And Galapagos Collaborate For GLPG0634, In Phase II To Treat Autoimmune Diseases
Nov 17, 2009: Galapagos Initiates Nanocort Phase II Clinical Trial For Multiple Sclerosis
Oct 07, 2009: Galapagos Achieves First Milestone In Anti-Infectives Alliance With GlaxoSmithKline
Sep 17, 2009: Galapagos collaborates With Charley’s Fund And Nash Avery Foundation To Develop SARM Candidate Drug For Duchenne Muscular Dystrophy
Sep 10, 2009: Galapagos Initiates Second Phase I Clinical Trial For GLPG0259
Aug 06, 2009: Galapagos Successfully Completes First Phase I Study For GLPG0259
Jul 23, 2009: Galapagos Achieves Milestone In Osteoporosis Collaboration With Lilly
Jun 16, 2009: Galapagos Initiates Clinical Studies With GLPG0187, A Candidate Drug For Bone Metastasis
Mar 27, 2009: Galapagos Enters The Clinic With Rheumatoid Arthritis Candidate Drug
Jan 19, 2009: Galapagos And GlaxoSmithKline Expand Anti-Infectives Alliance
Jan 09, 2009: Galapagos Enters Strategic Alliance In Diabetes And Obesity With Merck & Co., Inc.
Jan 05, 2009: Galapagos Selects Pre-clinical Candidate Drug For Cachexia
Financial Deals Landscape
Galapagos NV, Deals Summary
Galapagos NV, Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Galapagos Acquires Research Centre From GlaxoSmithKline
Galapagos Acquires Rights To GLPG0634 From GlaxoSmithKline
Galapagos Acquires Drug Discovery Service Operations Of Discovery Partners International
Partnerships
Abbott Enters Into Co-Development Agreement With Galapagos For Autoimmune Disease Drug
Les Laboratoires Servier Enters Into Co-Development Agreement With Galapagos
NovAliX Enters Into Drug Discovery Agreement With Galapagos
Argenta Discovery Extends Drug Discovery Agreement With Genentech
Argenta Discovery Enters Into Collaboration With Dr. Reddy’s Labs
Argenta Discovery Enters Into An Agreement With Janssen Pharmaceutica
Les Laboratoires Servier Enters Into Strategic Alliance With Galapagos
Galapagos Expands Co-Development Agreement With Roche
Galapagos Expands Its Collaboration Agreement With CHDI Foundation
MorphoSys Expands Antibody Alliance With Galapagos
Galapagos Enters Into Strategic Alliance With Roche Holding
Galapagos Extends Its Co-Development Agreement With GlaxoSmithKline
Galapagos Expands Co-Development Agreement With Merck & Co.
Galapagos Enters Into Research Agreement With University of Oxford
Galapagos Enters Into Agreement With Charley's Fund And THE NASH AVERY FOUNDATION
Argenta Discovery Enters Into Co-Development Agreement With Genentech
Galapagos Enters Into Collaboration With Opsona Therapeutics
Galapagos Enters Into Co-Development Agreement With Merck
Galapagos Expands Its Co-Development With GlaxoSmithKline
Galapagos Enters Into An Agreement With Merck
Galapagos Expands Its Co-Development Agreement With GlaxoSmithKline
Galapagos Expands Co-Development Agreement With Amgen
MorphoSys Enters Into Co-development Agreement With Galapagos
Bausch & Lomb Enters Into An Agreement With Galapagos
GlaxoSmithKline Enters Into Collaboration With Galapagos
Galapagos Enters Into Drug Discovery Agreement With Cystic Fibrosis Foundation Therapeutics
Galapagos Enters Into Collaboration With Janssen Pharmaceutica
Galapagos Expands Collaboration Agreement With GlaxoSmithKline
Galapagos Enters Into Collaboration Agreement With AstraZeneca
Galapagos Expands Its Drug Discovery Agreement With Cystic Fibrosis
LEO Pharma Enters Into Agreement With Galapagos
GlaxoSmithKline Enters Into Drug Development Alliance With Galapagos
Painceptor Pharma Enters Into Collaboration Agreement With Argenta Discovery
Dr. Reddy's Labs Enters Into An Agreement With Argenta Discovery
Licensing Agreements
Bausch & Lomb Enters Into Licensing Agreement With Galapagos
Galapagos Enter Into Agreement With Merck Serono
GlaxoSmithKline Exercises Option To License GLPG0778 And GLPG0555 From Galapagos
Galapagos Enters Into Licensing Agreement With Enceladus Pharma
Galapagos Enters Into Licensing Agreement With Eli Lilly And Company
Wyeth Enters Into Licensing Agreement With Galapagos
Galapagos Enters Into Licensing Agreement With Hillcrest Therapeutics
GeneGo Enters Into Licensing Agreement With Galapagos
Equity Offering
Galapagos Completes Private Placement Of Shares For $1.5 Million Upon Exercise Of Warrants
Galapagos Completes Private Placement Of $40.11 Million
Galapagos Completes Private Placement Of $27 Million
Galapagos Completes Private Placement Of $6 Million With GlaxoSmithKline
Galapagos Completes Private Placement Of $14 Million
Acquisition
Evotec Acquires Compound Focus
Galapagos Acquires Argenta Discovery
Galapagos Acquires Inpharmatica
ProStrakan Group Sells ProSkelia To Galapagos
Galapagos Acquires Discovery Partners, ChemRx, Xenometrix And Discovery Partners International From Infinity
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Galapagos NV, Key Information
Galapagos NV, Key Facts
Galapagos NV – Pipeline by Indication, 2012
Galapagos NV – Pipeline by Stage of Development, 2012
Galapagos NV – Monotherapy Products in Pipeline, 2012
Galapagos NV – Phase II, 2012
Galapagos NV – Phase I, 2012
Galapagos NV – Pre-Clinical, 2012
Galapagos NV – Discovery, 2012
Galapagos NV – Pipeline By Route of Administration, 2012
Galapagos NV – Pipeline Products By Mechanism of Action, 2012
Galapagos NV – Recent Pipeline Updates, 2012
Galapagos NV - Dormant Developmental Projects,2012
Galapagos NV - Discontinued Pipeline Products, 2012
Galapagos NV, Other Locations
Galapagos NV, Subsidiaries
Galapagos NV, Deals Summary
Galapagos Acquires Research Centre From GlaxoSmithKline
Galapagos Acquires Rights To GLPG0634 From GlaxoSmithKline
Galapagos Acquires Drug Discovery Service Operations Of Discovery Partners International
Abbott Enters Into Co-Development Agreement With Galapagos For Autoimmune Disease Drug
Les Laboratoires Servier Enters Into Co-Development Agreement With Galapagos
NovAliX Enters Into Drug Discovery Agreement With Galapagos
Argenta Discovery Extends Drug Discovery Agreement With Genentech
Argenta Discovery Enters Into Collaboration With Dr. Reddy’s Labs
Argenta Discovery Enters Into An Agreement With Janssen Pharmaceutica
Les Laboratoires Servier Enters Into Strategic Alliance With Galapagos
Galapagos Expands Co-Development Agreement With Roche
Galapagos Expands Its Collaboration Agreement With CHDI Foundation
MorphoSys Expands Antibody Alliance With Galapagos
Galapagos Enters Into Strategic Alliance With Roche Holding
Galapagos Extends Its Co-Development Agreement With GlaxoSmithKline
Galapagos Expands Co-Development Agreement With Merck & Co.
Galapagos Enters Into Research Agreement With University of Oxford
Galapagos Enters Into Agreement With Charley's Fund And THE NASH AVERY FOUNDATION
Argenta Discovery Enters Into Co-Development Agreement With Genentech
Galapagos Enters Into Collaboration With Opsona Therapeutics
Galapagos Enters Into Co-Development Agreement With Merck
Galapagos Expands Its Co-Development With GlaxoSmithKline
Galapagos Enters Into An Agreement With Merck
Galapagos Expands Its Co-Development Agreement With GlaxoSmithKline
Galapagos Expands Co-Development Agreement With Amgen
MorphoSys Enters Into Co-development Agreement With Galapagos
Bausch & Lomb Enters Into An Agreement With Galapagos
GlaxoSmithKline Enters Into Collaboration With Galapagos
Galapagos Enters Into Drug Discovery Agreement With Cystic Fibrosis Foundation Therapeutics
Galapagos Enters Into Collaboration With Janssen Pharmaceutica
Galapagos Expands Collaboration Agreement With GlaxoSmithKline
Galapagos Enters Into Collaboration Agreement With AstraZeneca
Galapagos Expands Its Drug Discovery Agreement With Cystic Fibrosis
LEO Pharma Enters Into Agreement With Galapagos
GlaxoSmithKline Enters Into Drug Development Alliance With Galapagos
Painceptor Pharma Enters Into Collaboration Agreement With Argenta Discovery
Dr. Reddy's Labs Enters Into An Agreement With Argenta Discovery
Bausch & Lomb Enters Into Licensing Agreement With Galapagos
Galapagos Enter Into Agreement With Merck Serono
GlaxoSmithKline Exercises Option To License GLPG0778 And GLPG0555 From Galapagos
Galapagos Enters Into Licensing Agreement With Enceladus Pharma
Galapagos Enters Into Licensing Agreement With Eli Lilly And Company
Wyeth Enters Into Licensing Agreement With Galapagos
Galapagos Enters Into Licensing Agreement With Hillcrest Therapeutics
GeneGo Enters Into Licensing Agreement With Galapagos
Galapagos Completes Private Placement Of Shares For $1.5 Million Upon Exercise Of Warrants
Galapagos Completes Private Placement Of $40.11 Million
Galapagos Completes Private Placement Of $27 Million
Galapagos Completes Private Placement Of $6 Million With GlaxoSmithKline
Galapagos Completes Private Placement Of $14 Million
Evotec Acquires Compound Focus
Galapagos Acquires Argenta Discovery
Galapagos Acquires Inpharmatica
ProStrakan Group Sells ProSkelia To Galapagos
Galapagos Acquires Discovery Partners, ChemRx, Xenometrix And Discovery Partners International From Infinity
List of Figures
Galapagos NV – Pipeline by Indication, 2012
Galapagos NV – Pipeline by Stage of Development, 2012
Galapagos NV – Monotherapy Products in Pipeline, 2012
Galapagos NV – Pipeline By Route of Administration, 2012
Galapagos NV - Pipeline Products By Mechanism of Action, 2012
Galapagos NV Overview
Key Information
Key Facts
Galapagos NV – Research and Development Overview
Key Therapeutic Areas
Galapagos NV – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Galapagos NV – Pipeline Products Glance
Galapagos NV Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Galapagos NV – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Galapagos NV – Drug Profiles
ADC-3322
Product Description
Mechanism of Action
R&D Progress
Antibody Program For Bone Disorders
Product Description
Mechanism of Action
R&D Progress
Cancer Program
Product Description
Mechanism of Action
R&D Progress
Drug For Alzheimer’s Disease
Product Description
Mechanism of Action
R&D Progress
Drug For COPD
Product Description
Mechanism of Action
R&D Progress
Drug For Cystic Fibrosis
Product Description
Mechanism of Action
R&D Progress
Drug For Diabetes And Obesity
Product Description
Mechanism of Action
R&D Progress
G-100192
Product Description
Mechanism of Action
R&D Progress
GLPG-0187
Product Description
Mechanism of Action
R&D Progress
GLPG-0492
Product Description
Mechanism of Action
R&D Progress
GLPG-0634
Product Description
Mechanism of Action
R&D Progress
GLPG-0974
Product Description
Mechanism of Action
R&D Progress
Osteoarthritis program
Product Description
Mechanism of Action
R&D Progress
Osteoporosis Program
Product Description
Mechanism of Action
R&D Progress
Galapagos NV – Pipeline Products by Route of Administration
Galapagos NV – Pipeline Products By Mechanism of Action
Galapagos NV – Recent Pipeline Updates
Galapagos NV - Dormant Projects
Galapagos NV - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
GLPG-0259
GLPG-0492
Galapagos NV – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Galapagos NV, Recent Developments
Galapagos NV- Press Release
Jun 05, 2012: Galapagos To Present GLPG0634 Phase II Proof Of Concept Results At EULAR Annual European Congress
May 14, 2012: Galapagos Initiates Phase IIa Study With GLPG0634
Feb 29, 2012: Abbott And Galapagos Collaborate For GLPG0634, In Phase II To Treat Autoimmune Diseases
Nov 17, 2009: Galapagos Initiates Nanocort Phase II Clinical Trial For Multiple Sclerosis
Oct 07, 2009: Galapagos Achieves First Milestone In Anti-Infectives Alliance With GlaxoSmithKline
Sep 17, 2009: Galapagos collaborates With Charley’s Fund And Nash Avery Foundation To Develop SARM Candidate Drug For Duchenne Muscular Dystrophy
Sep 10, 2009: Galapagos Initiates Second Phase I Clinical Trial For GLPG0259
Aug 06, 2009: Galapagos Successfully Completes First Phase I Study For GLPG0259
Jul 23, 2009: Galapagos Achieves Milestone In Osteoporosis Collaboration With Lilly
Jun 16, 2009: Galapagos Initiates Clinical Studies With GLPG0187, A Candidate Drug For Bone Metastasis
Mar 27, 2009: Galapagos Enters The Clinic With Rheumatoid Arthritis Candidate Drug
Jan 19, 2009: Galapagos And GlaxoSmithKline Expand Anti-Infectives Alliance
Jan 09, 2009: Galapagos Enters Strategic Alliance In Diabetes And Obesity With Merck & Co., Inc.
Jan 05, 2009: Galapagos Selects Pre-clinical Candidate Drug For Cachexia
Financial Deals Landscape
Galapagos NV, Deals Summary
Galapagos NV, Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Galapagos Acquires Research Centre From GlaxoSmithKline
Galapagos Acquires Rights To GLPG0634 From GlaxoSmithKline
Galapagos Acquires Drug Discovery Service Operations Of Discovery Partners International
Partnerships
Abbott Enters Into Co-Development Agreement With Galapagos For Autoimmune Disease Drug
Les Laboratoires Servier Enters Into Co-Development Agreement With Galapagos
NovAliX Enters Into Drug Discovery Agreement With Galapagos
Argenta Discovery Extends Drug Discovery Agreement With Genentech
Argenta Discovery Enters Into Collaboration With Dr. Reddy’s Labs
Argenta Discovery Enters Into An Agreement With Janssen Pharmaceutica
Les Laboratoires Servier Enters Into Strategic Alliance With Galapagos
Galapagos Expands Co-Development Agreement With Roche
Galapagos Expands Its Collaboration Agreement With CHDI Foundation
MorphoSys Expands Antibody Alliance With Galapagos
Galapagos Enters Into Strategic Alliance With Roche Holding
Galapagos Extends Its Co-Development Agreement With GlaxoSmithKline
Galapagos Expands Co-Development Agreement With Merck & Co.
Galapagos Enters Into Research Agreement With University of Oxford
Galapagos Enters Into Agreement With Charley's Fund And THE NASH AVERY FOUNDATION
Argenta Discovery Enters Into Co-Development Agreement With Genentech
Galapagos Enters Into Collaboration With Opsona Therapeutics
Galapagos Enters Into Co-Development Agreement With Merck
Galapagos Expands Its Co-Development With GlaxoSmithKline
Galapagos Enters Into An Agreement With Merck
Galapagos Expands Its Co-Development Agreement With GlaxoSmithKline
Galapagos Expands Co-Development Agreement With Amgen
MorphoSys Enters Into Co-development Agreement With Galapagos
Bausch & Lomb Enters Into An Agreement With Galapagos
GlaxoSmithKline Enters Into Collaboration With Galapagos
Galapagos Enters Into Drug Discovery Agreement With Cystic Fibrosis Foundation Therapeutics
Galapagos Enters Into Collaboration With Janssen Pharmaceutica
Galapagos Expands Collaboration Agreement With GlaxoSmithKline
Galapagos Enters Into Collaboration Agreement With AstraZeneca
Galapagos Expands Its Drug Discovery Agreement With Cystic Fibrosis
LEO Pharma Enters Into Agreement With Galapagos
GlaxoSmithKline Enters Into Drug Development Alliance With Galapagos
Painceptor Pharma Enters Into Collaboration Agreement With Argenta Discovery
Dr. Reddy's Labs Enters Into An Agreement With Argenta Discovery
Licensing Agreements
Bausch & Lomb Enters Into Licensing Agreement With Galapagos
Galapagos Enter Into Agreement With Merck Serono
GlaxoSmithKline Exercises Option To License GLPG0778 And GLPG0555 From Galapagos
Galapagos Enters Into Licensing Agreement With Enceladus Pharma
Galapagos Enters Into Licensing Agreement With Eli Lilly And Company
Wyeth Enters Into Licensing Agreement With Galapagos
Galapagos Enters Into Licensing Agreement With Hillcrest Therapeutics
GeneGo Enters Into Licensing Agreement With Galapagos
Equity Offering
Galapagos Completes Private Placement Of Shares For $1.5 Million Upon Exercise Of Warrants
Galapagos Completes Private Placement Of $40.11 Million
Galapagos Completes Private Placement Of $27 Million
Galapagos Completes Private Placement Of $6 Million With GlaxoSmithKline
Galapagos Completes Private Placement Of $14 Million
Acquisition
Evotec Acquires Compound Focus
Galapagos Acquires Argenta Discovery
Galapagos Acquires Inpharmatica
ProStrakan Group Sells ProSkelia To Galapagos
Galapagos Acquires Discovery Partners, ChemRx, Xenometrix And Discovery Partners International From Infinity
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Galapagos NV, Key Information
Galapagos NV, Key Facts
Galapagos NV – Pipeline by Indication, 2012
Galapagos NV – Pipeline by Stage of Development, 2012
Galapagos NV – Monotherapy Products in Pipeline, 2012
Galapagos NV – Phase II, 2012
Galapagos NV – Phase I, 2012
Galapagos NV – Pre-Clinical, 2012
Galapagos NV – Discovery, 2012
Galapagos NV – Pipeline By Route of Administration, 2012
Galapagos NV – Pipeline Products By Mechanism of Action, 2012
Galapagos NV – Recent Pipeline Updates, 2012
Galapagos NV - Dormant Developmental Projects,2012
Galapagos NV - Discontinued Pipeline Products, 2012
Galapagos NV, Other Locations
Galapagos NV, Subsidiaries
Galapagos NV, Deals Summary
Galapagos Acquires Research Centre From GlaxoSmithKline
Galapagos Acquires Rights To GLPG0634 From GlaxoSmithKline
Galapagos Acquires Drug Discovery Service Operations Of Discovery Partners International
Abbott Enters Into Co-Development Agreement With Galapagos For Autoimmune Disease Drug
Les Laboratoires Servier Enters Into Co-Development Agreement With Galapagos
NovAliX Enters Into Drug Discovery Agreement With Galapagos
Argenta Discovery Extends Drug Discovery Agreement With Genentech
Argenta Discovery Enters Into Collaboration With Dr. Reddy’s Labs
Argenta Discovery Enters Into An Agreement With Janssen Pharmaceutica
Les Laboratoires Servier Enters Into Strategic Alliance With Galapagos
Galapagos Expands Co-Development Agreement With Roche
Galapagos Expands Its Collaboration Agreement With CHDI Foundation
MorphoSys Expands Antibody Alliance With Galapagos
Galapagos Enters Into Strategic Alliance With Roche Holding
Galapagos Extends Its Co-Development Agreement With GlaxoSmithKline
Galapagos Expands Co-Development Agreement With Merck & Co.
Galapagos Enters Into Research Agreement With University of Oxford
Galapagos Enters Into Agreement With Charley's Fund And THE NASH AVERY FOUNDATION
Argenta Discovery Enters Into Co-Development Agreement With Genentech
Galapagos Enters Into Collaboration With Opsona Therapeutics
Galapagos Enters Into Co-Development Agreement With Merck
Galapagos Expands Its Co-Development With GlaxoSmithKline
Galapagos Enters Into An Agreement With Merck
Galapagos Expands Its Co-Development Agreement With GlaxoSmithKline
Galapagos Expands Co-Development Agreement With Amgen
MorphoSys Enters Into Co-development Agreement With Galapagos
Bausch & Lomb Enters Into An Agreement With Galapagos
GlaxoSmithKline Enters Into Collaboration With Galapagos
Galapagos Enters Into Drug Discovery Agreement With Cystic Fibrosis Foundation Therapeutics
Galapagos Enters Into Collaboration With Janssen Pharmaceutica
Galapagos Expands Collaboration Agreement With GlaxoSmithKline
Galapagos Enters Into Collaboration Agreement With AstraZeneca
Galapagos Expands Its Drug Discovery Agreement With Cystic Fibrosis
LEO Pharma Enters Into Agreement With Galapagos
GlaxoSmithKline Enters Into Drug Development Alliance With Galapagos
Painceptor Pharma Enters Into Collaboration Agreement With Argenta Discovery
Dr. Reddy's Labs Enters Into An Agreement With Argenta Discovery
Bausch & Lomb Enters Into Licensing Agreement With Galapagos
Galapagos Enter Into Agreement With Merck Serono
GlaxoSmithKline Exercises Option To License GLPG0778 And GLPG0555 From Galapagos
Galapagos Enters Into Licensing Agreement With Enceladus Pharma
Galapagos Enters Into Licensing Agreement With Eli Lilly And Company
Wyeth Enters Into Licensing Agreement With Galapagos
Galapagos Enters Into Licensing Agreement With Hillcrest Therapeutics
GeneGo Enters Into Licensing Agreement With Galapagos
Galapagos Completes Private Placement Of Shares For $1.5 Million Upon Exercise Of Warrants
Galapagos Completes Private Placement Of $40.11 Million
Galapagos Completes Private Placement Of $27 Million
Galapagos Completes Private Placement Of $6 Million With GlaxoSmithKline
Galapagos Completes Private Placement Of $14 Million
Evotec Acquires Compound Focus
Galapagos Acquires Argenta Discovery
Galapagos Acquires Inpharmatica
ProStrakan Group Sells ProSkelia To Galapagos
Galapagos Acquires Discovery Partners, ChemRx, Xenometrix And Discovery Partners International From Infinity
List of Figures
Galapagos NV – Pipeline by Indication, 2012
Galapagos NV – Pipeline by Stage of Development, 2012
Galapagos NV – Monotherapy Products in Pipeline, 2012
Galapagos NV – Pipeline By Route of Administration, 2012
Galapagos NV - Pipeline Products By Mechanism of Action, 2012